Clenoliximab

Clenoliximab
Clenoliximab ?
Monoclonal antibody
Type Whole antibody
Source Chimeric (primate/human)
Target CD4
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
ATC code None
Chemical data
Formula  ?
 N(what is this?)  (verify)

Clenoliximab (INN[1]) is a monoclonal antibody against CD4. It acts as an immunomodulator and has been investigated for the treatment of rheumatoid arthritis.[2] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[1]

References

  1. ^ a b World Health Organization (1997). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77". WHO Drug Information 11 (2): 89. http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list77.pdf. 
  2. ^ Hepburn, TW; Totoritis, MC; Davis, CB (2003). "Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis.". Rheumatology (Oxford, England) 42 (1): 54–61. doi:10.1093/rheumatology/keg030. PMID 12509613. 
v · d · eImmunomodulators: Immunosuppressive drugs / Immunosuppressants (L04)
Intracellular
(initiation)

purine synthesis inhibitors: Azathioprine • Mycophenolic acid

pyrimidine synthesis inhibitors: Leflunomide • Teriflunomide

antifolate: Methotrexate
Macrolides/
other IL-2 inhibitors
TNF-α inhibitor
Intracellular
(reception)
Sirolimus • Deforolimus • Everolimus • Temsirolimus • Zotarolimus • Biolimus A9
Extracellular
Serum target
(noncellular)
Cellular target
Unsorted
-cept (Fusion)

M: LMC

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug(L3/4)
v · d · eMonoclonal antibodies for the immune system
Immune system ("-l(i[m])-")
Human ("-limu-")

immunosuppression: Adalimumab • Atorolimumab • Brodalumab • Carlumab • Fresolimumab • Golimumab • Lerdelimumab • Mavrilimumab • Metelimumab • Morolimumab • Namilumab • Oxelumab • Sarilumab • Sifalimumab • Tabalumab • Urelumab

immune activation: Ipilimumab • Tremelimumab

other: Bertilimumab • Zanolimumab
Mouse ("-limo-")
Chimeric ("-lixi-")
Basiliximab • Clenoliximab • Galiximab • Gomiliximab • Infliximab • Keliximab • Lumiliximab • Priliximab • Teneliximab • Vapaliximab
Humanized ("-lizu-")
immunosuppressive: Aselizumab • Apolizumab • Benralizumab† • Cedelizumab • Certolizumab pegol • Daclizumab • Eculizumab • Efalizumab • Epratuzumab • Erlizumab • Etrolizumab • Fontolizumab • Itolizumab • Mepolizumab • Mogamulizumab • Natalizumab • Ocrelizumab • Omalizumab • Ozoralizumab • Pascolizumab • Pateclizumab • Pexelizumab • PRO 140† • Reslizumab • Rontalizumab • Rovelizumab • Ruplizumab • Samalizumab • Siplizumab • Talizumab • Teplizumab • Tocilizumab • Toralizumab • Tregalizumab • Vatelizumab • Vedolizumab • Visilizumab • TGN1412§
non-immunosuppressive: Ibalizumab†
Chimeric + humanized
("-lixizu-")
Interleukin ("-k(i[n])-")
Human ("-kinu-")
Briakinumab • Canakinumab • Fezakinumab • Secukinumab • Sirukumab • Tralokinumab • Ustekinumab
Humanized ("-kizu-", "-kinzu-")
Anrukinzumab • Enokizumab • Gevokizumab • Ixekizumab • Lebrikizumab • Olokizumab
Inflammatory lesions ("-les-")
Mouse ("-leso-")
Besilesomab • Fanolesomab‡ • Lemalesomab • Sulesomab
#WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III

M: LMC

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug(L3/4)


Stub icon This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.